Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.44 |
| ▸ | RORC | P51449 | 3/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20399800 | 0.84 | NPC1 (0.53) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL3183005 | 0.84 | MEN1 (0.52) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL9268608 | 0.83 | MEN1 (0.51) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL27799588 | 0.82 | MEN1 (0.50) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL1182778 | 0.80 | MEN1 (0.56) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL30360502 | 0.79 | NPC1 (0.48) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL20410742 | 0.79 | NPC1 (0.48) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL61861 | 0.79 | KMT2A (0.66) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL9268473 | 0.78 | MEN1 (0.49) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL30069356 | 0.78 | MEN1 (0.46) | MEN1KMT2ANPSR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3340988-B1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI INC (US) | 2025-04-09 | — | — | EP | disclosed |
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | AFASCI, INC. (US) | 2018-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | MEN1 2540/4885KMT2A 2232/4885NPSR1 576/4885 |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | CACNA1I, CACNA1G, CACNA1H | MEN1 2540/4885KMT2A 2232/4885NPSR1 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.